Interleukin-6 Downregulation with Mesenchymal Stem Cell Differentiation Results in Loss of Immunoprivilege

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2013 Jun 28

PMID 23802625

Citations 22

Authors

Peng Li

Shu-Hong Li

Jun Wu

Wang-Fu Zang

Sanjiv Dhingra

Lu Sun

Richard D Weisel

Ren-Ke Li

Affiliations

Soon will be listed here.

Abstract

Allogeneic mesenchymal stem cell (MSC) transplantation improves cardiac function, but cellular differentiation results in loss of immunoprivilege and rejection. To explore the mechanism involved in this immune rejection, we investigated the influence of interleukin-6 (IL-6), a factor secreted by MSCs, on immune privilege after myogenic, endothelial and smooth muscle cell differentiation induced by 5-azacytidine, VEGF, and transforming growth factor-β (TGF-β), respectively. Both RT-PCR and ELISA showed that myogenic differentiation of MSCs was associated with significant downregulation of IL-6 expression (P < 0.01), which was also observed following endothelial (P < 0.01) and smooth muscle cell differentiation (P < 0.05), indicating that IL-6 downregulation was dependent on differentiation but not cell phenotype. Flow cytometry demonstrated that IL-6 downregulation as a result of myogenic differentiation was associated with increased leucocyte-mediated cell death in an allogeneic leucocyte co-culture study (P < 0.01). The allogeneic reactivity associated with IL-6 downregulation was also observed following MSC differentiation to endothelial and smooth muscle cells (P < 0.01), demonstrating that leucocyte-mediated cytotoxicity was also dependent on differentiation but not cell phenotype. Restoration of IL-6 partially rescued the differentiated cells from leucocyte-mediated cell death. These findings suggest that rejection of allogeneic MSCs after implantation may be because of a reduction in cellular IL-6 levels, and restoration of IL-6 may be a new target to retain MSC immunoprivilege.

Citing Articles

Revolutionizing bone defect healing: the power of mesenchymal stem cells as seeds.

Zhang Y, Fan M, Zhang Y Front Bioeng Biotechnol. 2024; 12:1421674.

PMID: 39497791 PMC: 11532096. DOI: 10.3389/fbioe.2024.1421674.

The Immunological Profile of Adipose Mesenchymal Stromal/Stem Cells after Cell Expansion and Inflammatory Priming.

Buyl K, Merimi M, Rodrigues R, Rahmani S, Fayyad-Kazan M, Bouhtit F Biomolecules. 2024; 14(7).

PMID: 39062566 PMC: 11275169. DOI: 10.3390/biom14070852.

Multi-System-Level Analysis with RNA-Seq on Pterygium Inflammation Discovers Association between Inflammatory Responses, Oxidative Stress, and Oxidative Phosphorylation.

Kim Y, Choi Y, Kim T, Jeong J, Yu S, Kim T Int J Mol Sci. 2024; 25(9).

PMID: 38732006 PMC: 11083828. DOI: 10.3390/ijms25094789.

The IL-6 signaling pathway contributes critically to the immunomodulatory mechanism of human decidua-derived mesenchymal stromal cells.

Na H, Im K, Kim N, Lee J, Gil S, Min G iScience. 2024; 27(5):109783.

PMID: 38726369 PMC: 11079465. DOI: 10.1016/j.isci.2024.109783.

The Role of Doxycycline and IL-17 in Regenerative Potential of Periodontal Ligament Stem Cells: Implications in Periodontitis.

Okic dordevic I, Kukolj T, Zivanovic M, Momcilovic S, Obradovic H, Petrovic A Biomolecules. 2023; 13(10).

PMID: 37892119 PMC: 10604178. DOI: 10.3390/biom13101437.

References

Hare J, Traverse J, Henry T, Dib N, Strumpf R, Schulman S . A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54(24):2277-86. PMC: 3580848. DOI: 10.1016/j.jacc.2009.06.055. View

Bouffi C, Bony C, Courties G, Jorgensen C, Noel D . IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One. 2010; 5(12):e14247. PMC: 2998425. DOI: 10.1371/journal.pone.0014247. View

Fan M, Chen W, Liu W, Du G, Jiang S, Tian W . The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010; 13(4):429-38. DOI: 10.1089/rej.2009.0986. View

Huang X, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel R . Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 2010; 122(23):2419-29. DOI: 10.1161/CIRCULATIONAHA.110.955971. View

Spaggiari G, Capobianco A, Abdelrazik H, Becchetti F, Mingari M, Moretta L . Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2007; 111(3):1327-33. DOI: 10.1182/blood-2007-02-074997. View

Imanishi Y, Saito A, Komoda H, Kitagawa-Sakakida S, Miyagawa S, Kondoh H . Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol. 2008; 44(4):662-71. DOI: 10.1016/j.yjmcc.2007.11.001. View

Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Herve P . Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation. 2003; 108 Suppl 1:II253-8. DOI: 10.1161/01.cir.0000089186.09692.fa. View

Aggarwal S, Pittenger M . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2004; 105(4):1815-22. DOI: 10.1182/blood-2004-04-1559. View

Amado L, Saliaris A, Schuleri K, John M, Xie J, Cattaneo S . Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005; 102(32):11474-9. PMC: 1183573. DOI: 10.1073/pnas.0504388102. View

10.

Nemeth K, Leelahavanichkul A, Yuen P, Mayer B, Parmelee A, Doi K . Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2008; 15(1):42-9. PMC: 2706487. DOI: 10.1038/nm.1905. View

11.

Park C, Kim K, Bae S, Son H, Myung P, Hong H . Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J Stem Cells. 2014; 2(1):59-68. PMC: 4021795. DOI: 10.15283/ijsc.2009.2.1.59. View

12.

Pittenger M, Martin B . Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004; 95(1):9-20. DOI: 10.1161/01.RES.0000135902.99383.6f. View

13.

Williams A, Hare J . Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109(8):923-40. PMC: 3604746. DOI: 10.1161/CIRCRESAHA.111.243147. View

14.

Toma C, Pittenger M, Cahill K, Byrne B, Kessler P . Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105(1):93-8. DOI: 10.1161/hc0102.101442. View

15.

Chan C, Wu K, Lee Y, Hwang S, Lee M, Liao S . The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSCs, and adult-type MSCs. Transplantation. 2012; 94(2):132-8. DOI: 10.1097/TP.0b013e31825940a4. View

16.

Djouad F, Charbonnier L, Bouffi C, Louis-Plence P, Bony C, Apparailly F . Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007; 25(8):2025-32. DOI: 10.1634/stemcells.2006-0548. View

17.

Fedak P, Verma S, Weisel R, Li R . Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol. 2005; 14(1):1-11. DOI: 10.1016/j.carpath.2004.12.002. View

18.

Nagaya N, Kangawa K, Itoh T, Iwase T, Murakami S, Miyahara Y . Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005; 112(8):1128-35. DOI: 10.1161/CIRCULATIONAHA.104.500447. View

19.

Brunt K, Zhang Y, Mihic A, Li M, Li S, Xue P . Role of WNT/β-catenin signaling in rejuvenating myogenic differentiation of aged mesenchymal stem cells from cardiac patients. Am J Pathol. 2012; 181(6):2067-78. DOI: 10.1016/j.ajpath.2012.08.021. View

20.

Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O . HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31(10):890-6. DOI: 10.1016/s0301-472x(03)00110-3. View